Document is current
Any future updates will be listed below
-
Authors
ElAbd, Hesham https://orcid.org/0000-0003-1844-8279
Pesesky, Mitchell https://orcid.org/0000-0003-2066-7905
Innocenti, Gabriel
Chung, Brian K.
Mahdy, Aya K. H.
Kriukova, Valeriia
Kulsvehagen, Laila
Strobbe, Dennis
Stühler, Claudia
Mayr, Gabriele
May, Damon H. https://orcid.org/0000-0001-6902-3153
Prinzensteiner, Melanie https://orcid.org/0009-0002-8208-1141
Steiert, Tim A. https://orcid.org/0000-0002-0125-1173
Tran, Florian https://orcid.org/0000-0002-3735-9872
Hadjihannas, Michel V. https://orcid.org/0000-0001-6200-2675
Günther, Rainer
Rosati, Elisa https://orcid.org/0000-0002-2635-6422
Mucha, Sören https://orcid.org/0000-0002-1647-2526
Lieb, Wolfgang
Ziemann, Malte https://orcid.org/0000-0003-0919-0237
Dempfle, Astrid https://orcid.org/0000-0002-2618-3920
Braun, Felix
Folseraas, Trine
Hov, Johannes R. https://orcid.org/0000-0002-5900-8096
Melum, Espen https://orcid.org/0000-0001-6903-6878
Bacher, Petra
Sterneck, Martina
Weismüller, Tobias J. https://orcid.org/0000-0001-9736-1483
Lenzen, Henrike
Bokemeyer, Bernd
Howie, Bryan
Robins, Harlan S.
Röcken, Christoph https://orcid.org/0000-0002-6989-8002
Schreiber, Stefan https://orcid.org/0000-0003-2254-7771
Khanna, Nina https://orcid.org/0000-0002-2642-419X
Pröbstel, Anne-Katrin https://orcid.org/0000-0002-7748-1872
Schramm, Christoph https://orcid.org/0000-0002-4264-1928
Vogl, Thomas
Karlsen, Tom H. https://orcid.org/0000-0002-8289-9931
Franke, Andre https://orcid.org/0000-0003-1530-5811
- License Information
-
More Information
Article History
Received: 17 July 2024
Accepted: 31 March 2025
First Online: 11 June 2025
Competing interests
: M.P., D.H.M., B.H. and H.S.R. have or had employment and equity ownership with Adaptive Biotechnologies. H.E. did an internship at Adaptive biotechnologies from July 2023 until September 2023. F.T. received speaker’s fees from Abbvie, Bristol-Myers-Squibb, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals and Janssen, and funding from Sanofi/Regeneron. T.H.K. declares consulting fees from Albireo, Boehringer Ingelheim, MSD, Gilead and Falk Pharma unrelated to the present work. A.-K.P. (institution) has received speaker, consulting or travel honoraria from Novartis, Biogen, Roche and UCB all used for research support and unrelated to the present work. The other authors declare no competing interests.
